Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ra-223 plus alternative anti-androgen as first-line therapy for bone-metastatic CRPC
jRCTs031180442Completed
- Sponsor
- Bayer
- Start
- Mar 2018
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of radium-223 dichloride in prostate cancer (PCa), sponsored by Bayer. Primary endpoint: % change in ALP at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
radium-223 dichloride
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCTs031180442.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180442.